383 related articles for article (PubMed ID: 15586198)
1. [One man's loss is another man's gain].
Laake JH
Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3095. PubMed ID: 15586198
[No Abstract] [Full Text] [Related]
2. Professional pill pusher.
Meyer CR
Minn Med; 2005 Mar; 88(3):4. PubMed ID: 15852581
[No Abstract] [Full Text] [Related]
3. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
4. [The case of Vioxx requires consideration].
Håkansson J; Rosenberg P
Lakartidningen; 2004 Nov; 101(45):3494-5. PubMed ID: 15575421
[No Abstract] [Full Text] [Related]
5. [Expectations, hopes--and profit].
Haug C
Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3033. PubMed ID: 15586178
[No Abstract] [Full Text] [Related]
6. Was Vioxx really that dangerous?
Park A
Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
[No Abstract] [Full Text] [Related]
7. FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs.
FDA Consum; 2005; 39(3):7. PubMed ID: 16127812
[No Abstract] [Full Text] [Related]
8. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
Willis KD
Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
[No Abstract] [Full Text] [Related]
9. Withdrawal syndrome.
Nat Med; 2004 Nov; 10(11):1143. PubMed ID: 15516887
[No Abstract] [Full Text] [Related]
10. Painkiller in the dock.
Nature; 2005 Jul; 436(7050):459. PubMed ID: 16049447
[No Abstract] [Full Text] [Related]
11. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
12. [MSD about Vioxx--important to learn from the experience without hindsight].
Juhlin R
Lakartidningen; 2004 Nov; 101(46):3720-1. PubMed ID: 15586498
[No Abstract] [Full Text] [Related]
13. Merck withdraws Vioxx; FDA issues public health advisory.
FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
[No Abstract] [Full Text] [Related]
14. Why is this woman smiling? The hard sell of bad medicine.
Bloice C
Revolution (Oakl); 2005; 6(1):22-9. PubMed ID: 15822700
[No Abstract] [Full Text] [Related]
15. Merck's recall of rofecoxib--a strategic perspective.
Oberholzer-Gee F; Inamdar SN
N Engl J Med; 2004 Nov; 351(21):2147-9. PubMed ID: 15548771
[No Abstract] [Full Text] [Related]
16. [Rofecoxib--a recall with implications].
Hansen PR
Ugeskr Laeger; 2004 Dec; 166(50):4573. PubMed ID: 15633542
[No Abstract] [Full Text] [Related]
17. A bitter pill for one Merck critic.
McLean B
Fortune; 2004 Dec; 150(12):58. PubMed ID: 15617422
[No Abstract] [Full Text] [Related]
18. The pain game.
Wadman M
Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
[No Abstract] [Full Text] [Related]
19. The vexations of Vioxx.
Sibbald B
CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
[No Abstract] [Full Text] [Related]
20. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
[Next] [New Search]
